Chemokine Therapeutics Corp.

VANCOUVER, March 22 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. (the "Company") (Toronto Stock Exchange: CTI; OTCBB: CHKT), a biotechnology company developing peptide-based therapies to treat cancer, blood disorders, cardiovascular and infectious disease, announced that today it placed 5,471,698 common shares (the "Shares") with a group of primarily institutional investors at a price of CDN$1.06 per Share for gross proceeds of CDN$5.8 million.

Comment - This looks like a quality financing. I'm surprised the stocks not reacting to this news. This company has 2 products in clinical trials. Pay attention. Any thoughts?